FDA-cleared profile

Sonic DL

GE Medical Systems,LLC (GE Healthcare) · MRI · FDA-cleared (510(k))

Sonic DL is deep-learning MRI reconstruction for highly undersampled or accelerated cardiac acquisitions on compatible GE 1.5T and 3.0T MRI systems for pediatric and adult patients.

Clinical role
Integrated MR reconstruction that accelerates acquisition or changes image appearance before routine professional interpretation.
Images and patients
MRI · Heart/Cardiovascular
Key limitation
Available for use on GE Healthcare 1.5T and 3.0T MR systems; intended for cardiac imaging and patients of all ages.

Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • Imaging and anatomyMRI · Heart/Cardiovascular
  • Workflow roleIntegrated MR reconstruction that accelerates acquisition or changes image appearance before routine professional interpretation.
  • Required inputData from MR cardiac cine exams obtained using a highly accelerated acquisition technique.
  • Output and human actionMR images reconstructed from highly under-sampled data, enabling highly accelerated acquisitions.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Sonic DL is deep-learning MRI reconstruction for highly undersampled or accelerated cardiac acquisitions on compatible GE 1.5T and 3.0T MRI systems for pediatric and adult patients.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Workflow role
Integrated MR reconstruction that accelerates acquisition or changes image appearance before routine professional interpretation.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
Data from MR cardiac cine exams obtained using a highly accelerated acquisition technique.
  • Exact FDA submission
  • Checked 2026-09-19

The exact device description states the source and type of data to which the reconstruction algorithm is applied.

Output and clinician action
MR images reconstructed from highly under-sampled data, enabling highly accelerated acquisitions.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indications for use state the reconstruction output and acceleration purpose without adding unsupported export or archival claims.

Care setting
Hospital and outpatient MRI departments using compatible scanner models and release-specific sequences.
  • Exact FDA submission
  • Checked 2026-09-03
Limitations
Available for use on GE Healthcare 1.5T and 3.0T MR systems; intended for cardiac imaging and patients of all ages.
  • Exact FDA submission
  • Checked 2026-09-19

The exact indications for use define the supported field strengths, cardiac scope, and patient age scope.

Evidence summary
K223523 reports 57 unique subjects, 107 image series from seven sites, and reader studies involving three radiologists, including cardiac pathology and healthy-volunteer image-quality comparisons. The public FDA summary supports the tested accelerated cardiac MR workflow but does not provide a single general sensitivity or specificity claim.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K223523 reports 57 unique subjects, 107 image series from seven sites, and reader studies involving three radiologists, including cardiac pathology and healthy-volunteer image-quality comparisons. The public FDA summary supports the tested accelerated cardiac MR workflow but does not provide a single general sensitivity or specificity claim.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary endpoint for this system, reconstruction, segmentation, guidance, or quantitative function. Use the task-specific evidence below.

Unique validation subjects

57 subjects

  • EndpointSonic DL cardiac-MR validation
  • PopulationSonic DL
  • Tested versionSonic DL

Image-series evaluations

107 series

  • EndpointSonic DL cardiac-MR validation
  • PopulationSonic DL
  • Tested versionSonic DL

Validation sites

7 sites

  • EndpointSonic DL cardiac-MR validation
  • PopulationSonic DL
  • Tested versionSonic DL

Reader radiologists

3 readers

  • EndpointSonic DL cardiac-MR reader study
  • PopulationSonic DL
  • Tested versionSonic DL

K223523 FDA performance package for Sonic DL

  • DesignManufacturer accelerated cardiac-MR reconstruction, image-quality, reader, and accuracy validation
  • Population57 unique subjects, including 46 patients and 11 healthy participants, across 7 sites and cardiac pathologies
  • Scopeexact submission
  • Tested versionSonic DL
  • IndependenceSponsor or vendor study

K223523

Manufacturer evidence submitted for FDA clearance or approval; local clinical, technical, and workflow acceptance remains necessary.

4 unlinked candidate evidence records are retained for source review and excluded from this evidence display.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K223523 by exact submission identifier. This does not exclude product-family, later, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

Exact-identifier review does not prove absence of all product-family safety signals.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the product within the applicable imaging, procedural, or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance or approval.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Data from MR cardiac cine exams obtained using a highly accelerated acquisition technique.

    Scope: Exact FDA submission. The exact device description states the source and type of data to which the reconstruction algorithm is applied.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K223523: Sonic DL

  2. Routing

    Source context, not route validation: Integrated scanner reconstruction followed by normal DICOM delivery; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.

    Scope: Product family. Current vendor materials are product-family evidence for K223523; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K223523: Sonic DL · GE HealthCare Sonic DL announcement

  3. AI processing

    Source context, not route validation: Licensed reconstruction software integrated into the specified MRI scanner configurations.

    Scope: Product family. Current vendor materials are product-family evidence for K223523; confirm the exact cleared version, enabled options, deployment, and local compatibility.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K223523: Sonic DL · GE HealthCare Sonic DL announcement

  4. Returned objects

    Source context, not route validation: MR images reconstructed from highly under-sampled data, enabling highly accelerated acquisitions.

    Scope: Exact FDA submission. The exact indications for use state the reconstruction output and acceleration purpose without adding unsupported export or archival claims.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K223523: Sonic DL

  5. Viewer/worklist/report

    Unresolved route: MR images reconstructed from highly under-sampled data, enabling highly accelerated acquisitions.

    Scope: Exact FDA submission. The exact indications for use state the reconstruction output and acceleration purpose without adding unsupported export or archival claims.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K223523: Sonic DL

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
Licensed reconstruction software integrated into the specified MRI scanner configurations.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K223523; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Integration
Integrated scanner reconstruction followed by normal DICOM delivery; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K223523; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Security
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
  • Vendor-wide
  • Checked 2026-10-26

Vendor statement, not an attestation. Identity bridge: GE HealthCare's own Privacy Shield page on gehealthcare.com names GE Medical Systems LLC as a US entity of the GEHC group. Corporate program statement; portal content is credentialed; exact-release scope is not established.

Training
Only qualified mri technologists and interpreting physicians should operate or interpret the product. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Performance depends on scanner, field strength, coil, sequence, anatomy, acceleration, input quality, and reconstruction setting; reconstructed images remain subject to physician review.
  • Product family
  • Checked 2026-09-03

Current vendor materials are product-family evidence for K223523; confirm the exact cleared version, enabled options, deployment, and local compatibility.

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, outputs, and enabled AI functions to K223523 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Integrated scanner reconstruction followed by normal DICOM delivery; validate reconstruction labels, geometry, quantitative values, PACS display, and downstream compatibility.

product family · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Performance depends on scanner, field strength, coil, sequence, anatomy, acceleration, input quality, and reconstruction setting; reconstructed images remain subject to physician review.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

No exact-product price was found in the reviewed public material; vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Performance depends on scanner, field strength, coil, sequence, anatomy, acceleration, input quality, and reconstruction setting; reconstructed images remain subject to physician review.

product family · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. Vendor statements are current product-family context; confirm the exact cleared release and installed options.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K223523
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Heart/Cardiovascular
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-05-30
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-19Last searched
26Fields reviewed
12Source classes checked
7Awaiting review PubMed leads
1Awaiting review trial leads
0Unreviewed FDA recall leads

Recovered from the prior exact-submission extraction and normalized under the current provenance rules. Exact FDA support assessed on 2026-09-19. Packet-supported facts: purpose, modality, anatomy; packet-unavailable facts: intendedUsers, input, output, limitations, evidenceSummary. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 7 PubMed and 1 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads remain unpublished until a human confirms the exact product and tested version.

Source classes: fda ai list, fda decision summary, fda decision material, vendor product page, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, fda decision summary packet, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Intended users: Withdrawn - checked 2026-09-19 - Exact FDA submission

    Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

16 sources - 2 history items

Source ledger

  1. FDA K223523: Sonic DL

    U.S. Food and Drug Administration - Published 2023-05-30 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. GE HealthCare Sonic DL announcement

    GE HealthCare - Accessed 2026-09-03

    Scope: integration, deployment, monitoring, productFamilyContext

  8. Clinical utility of a rapid two-dimensional balanced steady-state free precession sequence with deep learning reconstruction.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  9. Clinical evaluation of deep learning-accelerated 3D FLAIR imaging at 1.5T and 3T for visualization of cerebral white matter lesions.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  10. Qualitative and Quantitative Evaluation of a Deep Learning-Based Reconstruction for Accelerated Cardiac Cine Imaging.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  11. Deep Learning-Accelerated 3D Vessel Wall MRI: Prospective Evaluation of Sonic DL with Substantial Scan Time Reduction.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  12. Fast cardiac magnetic resonance (CMR) protocol for biventricular functional assessment and tissue characterisation.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  13. Clinical evaluation of deep learning accelerated 3D magnetic resonance cholangiopancreatography at 1.5 T and 3 T.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  14. High-Resolution 2D versus 3D Lumbar Spine MRI Optimized with a Deep Learning Reconstruction Algorithm and Prototype Conformal Coil.

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  15. Screening and Staging of Benign vs Malignant Pelvic Abnormalities

    U.S. National Library of Medicine - Accessed 2026-09-03

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  16. GE HealthCare: Product Security (portal and Cybersecurity Risk Management System)

    GE HealthCare - Accessed 2026-10-26

    Scope: security

Research history

  1. K223523 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

Alternatives

Related tools to compare

FDA-cleared K252084

AI4CMR v2.0

Ai4medimaging Medical Solutions S.A.

Authorized purpose: Cardiac MRI ventricular function and 2D phase-contrast flow quantification

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2026-02-11
FDA-cleared K241922

Myomics

Phantomics Inc.

Authorized purpose: Myomics assists qualified medical professionals with viewing, post-processing and qualitative/quantitative evaluation of 3T cardiovascular MR images in DICOM format, including heart and adjacent-vessel measurements; semi-automated machine-learning workflows are intended for adults and contribute to comprehensive diagnostic decision-making.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2025-02-28
FDA-cleared K183274

RTHawk, HeartVista Cardiac Package

HeartVista, Inc.

Accessory acquisition, reconstruction, and display of cardiovascular MR images on compatible 1.5T and 3T whole-body MRI systems for trained-physician interpretation.

Modality
MRI
Anatomy
Heart/Cardiovascular
Decision
2019-10-18

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history